Bayer's Kidney Drug Shows Efficacy Against Heart Failure in Late-Stage Trial
By Adria Calatayud
Bayer said its Kerendia kidney-disease drug met a primary goal of a late-stage trial by showing efficacy in patients with heart failure.
The German pharmaceutical and agricultural group said Monday that the drug significantly reduced cardiovascular death and total heart-failure events compared to placebo in addition to usual therapy in a phase 3 clinical study. The drug was well tolerated in the trial, the company added.
Bayer said it would discuss the trial data with health authorities regarding an application of marketing authorization for the condition.
Finerenone, commercialized as Kerendia and Firialta, is already approved for the treatment of adult patients with chronic kidney disease linked to type 2 diabetes in more than 90 countries, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
August 05, 2024 03:04 ET (07:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now